253 related articles for article (PubMed ID: 31100410)
1. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
2. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
3. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Geng X; Xie L; Xing H
Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
[TBL] [Abstract][Full Text] [Related]
4. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
5. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
6. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma.
Mao X; Chen Z; Zhao Y; Yu Y; Guan S; Woodfield SE; Vasudevan SA; Tao L; Pang JC; Lu J; Zhang H; Zhang F; Yang J
Oncotarget; 2017 Jan; 8(1):1555-1568. PubMed ID: 27902463
[TBL] [Abstract][Full Text] [Related]
7. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways.
Cheng J; Fan YH; Xu X; Zhang H; Dou J; Tang Y; Zhong X; Rojas Y; Yu Y; Zhao Y; Vasudevan SA; Zhang H; Nuchtern JG; Kim ES; Chen X; Lu F; Yang J
Cell Death Dis; 2014 Feb; 5(2):e1079. PubMed ID: 24556694
[TBL] [Abstract][Full Text] [Related]
8. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
[TBL] [Abstract][Full Text] [Related]
9. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
10. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
11. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
[TBL] [Abstract][Full Text] [Related]
12. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
13. The synergistic antitumor effect of combination therapy with a MEK inhibitor and YAP inhibitor on pERK-positive neuroblastoma.
Takemoto M; Tanaka T; Tsuji R; Togashi Y; Higashi M; Fumino S; Tajiri T
Biochem Biophys Res Commun; 2021 Sep; 570():41-46. PubMed ID: 34271435
[TBL] [Abstract][Full Text] [Related]
14. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L; Scorsone K; Woodfield SE; Zage PE
Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
[TBL] [Abstract][Full Text] [Related]
16. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
Li H; Wang Y; Chen Z; Lu J; Pan J; Yu Y; Zhao Y; Zhang H; Hu T; Liu Q; Yang J
Oncotarget; 2017 Jan; 8(4):5874-5884. PubMed ID: 27564113
[TBL] [Abstract][Full Text] [Related]
17. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA SNHG16 regulates cell behaviors through miR-542-3p/HNF4α axis via RAS/RAF/MEK/ERK signaling pathway in pediatric neuroblastoma cells.
Deng D; Yang S; Wang X
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32412051
[TBL] [Abstract][Full Text] [Related]
19. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
[TBL] [Abstract][Full Text] [Related]
20. TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
Komar-Stossel C; Gross E; Dery E; Corchia N; Meir K; Fried I; Abramovitch R
PLoS One; 2014; 9(3):e90224. PubMed ID: 24603724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
